AI Biotechnology LLC, Access Industries Holdings LLC, Access Industries Management LLC, and Len Blavatnik filed Amendment No. 1 to Schedule 13G with the SEC on November 6, 2026, disclosing a combined beneficial ownership position in Latigo Biotherapeutics, Inc. common stock as of September 3, 2026.
Key Highlights
- Aggregate beneficial ownership: Each reporting person is associated with 3,193,565 shares of Latigo Biotherapeutics common stock (par value $0.0001 per share).
- Percent of class: The 3,193,565 shares represent 4.8% of common stock outstanding, based on 66,299,347 shares outstanding as of November 2, 2026.
- Voting and dispositive power: All 3,193,565 shares are held with shared voting power and shared dispositive power; sole voting and sole dispositive power are each reported as 0.
- Direct holder: According to the filing, the shares are held directly by AI Biotechnology LLC; beneficial ownership is attributed to Access Industries Holdings LLC, Access Industries Management LLC, and Len Blavatnik through a chain of control.
- Triggering event: The date of the event requiring this filing is stated as September 3, 2026.
- Ownership threshold: The filing designates this position as ownership of 5 percent or less of a class under Item 5.
Access Industries Group Discloses Sub-5% Stake in Latigo Biotherapeutics
According to the filing, 3,193,565 shares of Latigo Biotherapeutics, Inc. common stock are held directly by AI Biotechnology LLC. The filing further states that those shares "may also be deemed to be beneficially owned by AIH, AIM and Mr. Blavatnik because (i) Mr. Blavatnik controls AIM and holds a majority of the outstanding voting interests in AIH, (ii) AIM controls AIH, and (iii) AIH controls all of the outstanding voting interests in AI Biotechnology." Each of the reporting persons other than AI Biotechnology, along with their affiliated entities and the officers, partners, members, and managers thereof, "disclaims beneficial ownership of these securities," the filing states.
The percentage of class, reported as 4.8%, is calculated based on 66,299,347 shares of common stock outstanding as of November 2, 2026, as reported in Latigo Biotherapeutics' Form 10-Q filed with the SEC on November 5, 2026, according to the filing. The principal business office of each reporting person is listed as c/o Access Industries, Inc., 40 West 57th Street, 28th Floor, New York, NY 10019. AI Biotechnology LLC, Access Industries Holdings LLC, and Access Industries Management LLC are each organized under the laws of the State of Delaware, while Len Blavatnik is identified as a citizen of the United States of America.
The filing was signed on November 6, 2026, by Alejandro Moreno, identified as Executive Vice President of Access Industries Management LLC. Moreno also signed on behalf of Len Blavatnik as attorney-in-fact. The certification accompanying the filing states that the securities "were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."
What Was Disclosed
Four reporting persons affiliated with the Access Industries group filed Amendment No. 1 to Schedule 13G disclosing shared beneficial ownership of 3,193,565 shares, or 4.8%, of Latigo Biotherapeutics, Inc. common stock, with the triggering event dated September 3, 2026.




Please wait processing your request...